Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer

Background The role of adjuvant chemotherapy has not yet been established for patients with resected biliary tract cancer. S-1 has been shown to exert activity against advanced biliary tract cancer. Therefore, we evaluated the feasibility of adjuvant chemotherapy with S-1 in patients with resected b...

Full description

Saved in:
Bibliographic Details
Published in:International journal of clinical oncology 2018-10, Vol.23 (5), p.894-899
Main Authors: Nakachi, Kohei, Konishi, Masaru, Ikeda, Masafumi, Shimada, Kazuaki, Okusaka, Takuji, Saiura, Akio, Ishii, Hiroshi, Sugiyama, Masanori, Furuse, Junji, Sakamoto, Hirohiko, Shimamura, Tomotaka, Ohta, Takehiro
Format: Article
Language:English
Subjects:
Adult
Aged
Antimetabolites, Antineoplastic - therapeutic use
Bile
Bile ducts
Biliary tract
Biliary Tract Neoplasms - drug therapy
Biliary Tract Neoplasms - pathology
Biliary Tract Neoplasms - surgery
Cancer
Cancer Research
Cancer therapies
Carcinoma, Papillary - drug therapy
Carcinoma, Papillary - pathology
Carcinoma, Papillary - surgery
Carcinoma, Signet Ring Cell - drug therapy
Carcinoma, Signet Ring Cell - pathology
Carcinoma, Signet Ring Cell - surgery
Chemotherapy
Chemotherapy, Adjuvant
Cholangiocarcinoma
Diarrhea
Drug Combinations
Feasibility Studies
Female
Gallbladder
Humans
Male
Medicine
Medicine & Public Health
Middle Aged
Nausea
Neoplasm Recurrence, Local - diagnosis
Neutropenia
Neutropenia - chemically induced
Oncology
Original Article
Oxonic Acid - therapeutic use
Patients
Postoperative Period
Prognosis
Surgical Oncology
Survival
Survival Rate
Tegafur - therapeutic use
Toxicity
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The role of adjuvant chemotherapy has not yet been established for patients with resected biliary tract cancer. S-1 has been shown to exert activity against advanced biliary tract cancer. Therefore, we evaluated the feasibility of adjuvant chemotherapy with S-1 in patients with resected biliary tract cancer. Methods Patients with complete macroscopic resection of intrahepatic/extrahepatic bile duct, gall bladder, or ampullary cancer were eligible. S-1 was administered orally twice daily for 4 weeks every 6 weeks, up to 4 cycles. The treatment was continued up to 24 weeks or until recurrence/appearance of unacceptable toxicity. The primary endpoint was the treatment completion rate, which was defined as the percentage of patients who received a relative dose intensity of ≥ 75%. This trial was registered as UMIN000004051. Results Thirty-three patients were enrolled between June 2010 and March 2011. The relative dose intensity was ≥ 75% in 27 patients representing a treatment completion rate of 81.8%. The most common grade 3/4 adverse event was neutropenia (18%). Grade 2 nausea or diarrhea was observed in 12%. The 3-year relapse-free survival rate was 39.4%. The 3-year survival rate was 54.5%. Conclusion Adjuvant chemotherapy with S-1 is feasible treatment in patients with resected biliary tract cancer. It is necessary to conduct a phase III study to confirm the efficacy of adjuvant therapy of S-1 in patients with resected BTC.
ISSN:1341-9625
1437-7772
DOI:10.1007/s10147-018-1283-6